TY - JOUR
T1 - Vitiligo
T2 - an update on systemic treatments
AU - Searle, T.
AU - Al-Niaimi, F.
AU - Ali, F. R.
PY - 2021/3
Y1 - 2021/3
N2 - Summary Vitiligo is an autoimmune skin condition characterized by depigmented macules and patches, and has a huge psychosocial impact on patients. Treatment of vitiligo aims to prevent the spread of disease and facilitate repigmentation of affected lesions. The mainstay of treatment for unstable vitiligo has been topical agents (corticosteroids, calcineurin inhibitors) and phototherapy. However, systemic treatments are increasingly being shown to have a significant impact on the course of the disease as monotherapy or adjunctive therapy. Of note, oral mini-pulsed corticosteroid therapy, methotrexate, minocycline, ciclosporin, Janus kinase inhibitors and certain supplements have been used in the systemic treatment of vitiligo. We review the underlying evidence supporting the use of each of these systemic treatments.
AB - Summary Vitiligo is an autoimmune skin condition characterized by depigmented macules and patches, and has a huge psychosocial impact on patients. Treatment of vitiligo aims to prevent the spread of disease and facilitate repigmentation of affected lesions. The mainstay of treatment for unstable vitiligo has been topical agents (corticosteroids, calcineurin inhibitors) and phototherapy. However, systemic treatments are increasingly being shown to have a significant impact on the course of the disease as monotherapy or adjunctive therapy. Of note, oral mini-pulsed corticosteroid therapy, methotrexate, minocycline, ciclosporin, Janus kinase inhibitors and certain supplements have been used in the systemic treatment of vitiligo. We review the underlying evidence supporting the use of each of these systemic treatments.
UR - http://www.scopus.com/inward/record.url?scp=85097889302&partnerID=8YFLogxK
U2 - 10.1111/ced.14435
DO - 10.1111/ced.14435
M3 - Review article
SN - 0307-6938
VL - 46
SP - 248
EP - 258
JO - Clinical and Experimental Dermatology
JF - Clinical and Experimental Dermatology
IS - 2
ER -